APH

ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCQB: APCSF) (the "Company" or "ALDA") announces that its Annual General Meeting of shareholders was held in Vancouver, British Columbia on December 10, 2010 at which:

--  the incumbent directors of the Company, being Terrance Owen, Peter Chen,
    Linda Allison, Ronald Zokol, Eugene Hodgson and William F. McCoy were
    re-elected as directors of ALDA for the coming year;
--  Meyers Norris Penny LLP, Chartered Accountants, formed by way of a
    merger involving HLB Cinnamon Jang Willoughby during the financial year
    ending June 30, 2010, were appointed as new auditors of ALDA for the
    coming year; and
--  in accordance with the policies of the TSX Venture Exchange, the
    Company's rolling 2003 Incentive Stock Option Plan, as amended, was
    ratified for the coming year.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor Relations 604-377-5781 or 604-521-8300 Ext 203 scott_young@aldacorp.com www.aldacorp.com